South Carolina Kratom Law: The 2% 7-OH Cap That Disappeared

South Carolina lawmakers have spent two years drawing lines around kratom: natural or synthetic, two percent or twenty milligrams, leaf or extract, isolated or concentrated. The record shows exactly how those lines moved.

A Family Is Asking What “Consumer Protection” Meant

FOX Carolina reported September 22, 2026 that Robert and Dana Knox are mourning their 29-year-old son, Micah. His parents said he had been sober for nine and a half months. The report says toxicology found mitragynine in his blood and describes his death as an accidental overdose.

Robert Knox told FOX Carolina: “He didn’t deserve to die from something that he bought at a gas station.”

The report does not establish that 7-OH itself caused Micah's death. It does raise a direct question for a state that already enacted a law called the Kratom Consumer Protection Act: what did the law actually prohibit, and how could regulators verify compliance?

The 2% Limit Was There. Then It Was Gone.

The April 15, 2025 version of S.221 prohibited a product containing more than 2% 7-hydroxymitragynine in the alkaloid fraction. The Senate Medical Affairs Committee later proposed an amendment deleting that numerical ceiling and narrowing the synthetic language to “fully synthetic” alkaloids. Sen. Penry Gustafson Garrett explained the committee amendment on the floor. The Senate adopted it and passed the bill 39-0. Gov. Henry McMaster signed S.221 on May 12, 2025.

The enacted KCPA requires labels to disclose the amount of mitragynine and 7-OH, but contains no 2% ceiling. Its synthetic prohibition applies to a fully synthetic alkaloid.

South Carolina Senator Daniel Verdin — **Sen. Daniel Verdin** — Chairman of the Senate Medical Affairs Committee. Verdin signed the committee report recommending passage of S.221 as amended. That committee amendment removed the bill’s proposed 2% 7-hydroxymitragynine limit, and the amended KCPA advanced without that numerical cap.

A KCPA Is Only as Strong as Its Enforcement

A clerk or ordinary retail inspector cannot determine by sight whether a tablet contains 1.9% or 2.1% 7-OH, whether a labeled milligram amount is accurate, whether isolated 7-OH was added, or how an alkaloid was manufactured. Those questions require testing, traceability and—where the law turns on manufacturing origin—evidence about the production process.

That is the practical problem with increasingly intricate chemical carve-outs. Every percentage, milligram ceiling and synthetic-versus-natural distinction creates another fact the state must independently verify.

Restroom image illustrating the limits of paper-only consumer protection — **Our assessment of the amended H.4641:** this is about how much protection a paper KCPA provides when compliance depends on chemical distinctions, concentration limits and certificates that cannot be verified by looking at the product on a store shelf.

Then H.4641 Started as a Schedule I Bill

H.4641 was introduced to add kratom to Schedule I and repeal the KCPA. The House Judiciary Committee substituted a regulatory approach. Rep. William Bailey then offered an amendment restoring broad Schedule I treatment and repeal. Rep. James Rutherford moved to table it; the motion succeeded 54-45.

On April 29, the House considered additional amendments. Rep. Case Brittain moved to table proposals addressing synthetic compounds and 7-OH and moved to table Rep. John McCravy's broad Schedule I/repeal proposal. Brittain also offered a detailed KCPA rewrite; it was tabled. Rutherford offered another KCPA rewrite with a 20 mg 7-OH ceiling and retail-location restrictions; it too was tabled.

Bill & Amendment Tracker

Measure	Who / Action	7-OH / Kratom Treatment	Outcome
S.221 · Apr. 15, 2025	Senate Medical Affairs version	Prohibited >2% 7-OH in alkaloid fraction; addressed synthetic alkaloids.	Later amended
S.221 committee amendment · Apr. 24	Medical Affairs; Sen. Garrett explained	Deleted 2% ceiling; changed synthetic language to “fully synthetic.”	Adopted; Senate 39-0
S.221 / Act 35	Gov. McMaster signed May 12	No numerical 7-OH ceiling; label must disclose mitragynine and 7-OH; fully synthetic alkaloids prohibited.	Enacted
H.4641 as introduced	Pope et al.	Add kratom to Schedule I and repeal KCPA.	Rewritten in House
Judiciary Amd. 1 · Apr. 21, 2026	Rep. Brittain explained	Substituted KCPA-style regulatory language for introduced ban structure.	Adopted
Bailey Amd. 2 · Apr. 21	Rutherford moved to table	Restore broad Schedule I + repeal KCPA.	Tabled 54-45
Bailey/Chapman Amd. 3 · Apr. 29	Pope explained; Brittain supported	Schedule broad chemically equivalent kratom alkaloids, expressly including mitragynine and 7-OH.	Adopted
Bailey/Chapman Amd. 6	Brittain moved to table	Schedule synthetic kratom-related alkaloids, including synthetic mitragynine and 7-OH.	Tabled
McCravy Amd. 7	Brittain moved to table	Broaden synthetic prohibition and schedule any 7-OH compound.	Tabled
McCravy Amd. 8	Brittain moved to table	Broad Schedule I language + repeal KCPA.	Tabled
Brittain Amd. 9	Rep. Brittain	KCPA rewrite: 2% threshold; no added isolated/concentrated 7-OH; COA/testing provisions.	Tabled
Rutherford Amd. 10	Rep. Rutherford	KCPA rewrite with 20 mg 7-OH limit and retail-location restrictions.	Tabled
H.4641 House passage	House	Amended bill passed 87-7 on second reading and 98-4 on third reading; sent to Senate Medical Affairs.	Pending in Senate record

South Carolina Representative Case Brittain — **Rep. Case Brittain** — In the 2026 H.4641 debate, Brittain explained the Judiciary Committee rewrite, moved to table multiple amendments—including McCravy's broad Schedule I/KCPA-repeal proposal—and offered his own KCPA rewrite with a 2% 7-OH threshold, a prohibition on added isolated or concentrated 7-OH, and COA/testing provisions. His amendment was tabled.

South Carolina Representative James Rutherford — **Rep. James Rutherford** — Rutherford moved to table Bailey's amendment that would have restored broad Schedule I treatment and repealed the KCPA; the motion succeeded 54-45. He later offered a KCPA rewrite allowing up to 20 mg of 7-OH per serving/package unit while adding retail-location restrictions. That amendment was tabled.

DOJ and DEA Have Already Put MP, MGM-15 and MGM-16 in Schedule I

The federal landscape is no longer hypothetical. On August 25, 2026, the U.S. Department of Justice announced the emergency scheduling of three potent 7-OH-related opioid compounds: mitragynine pseudoindoxyl (MGPI/MP), MGM-15 and MGM-16. DEA temporarily placed all three into Schedule I of the federal Controlled Substances Act.

DOJ said the action subjects the manufacture, distribution and possession of those substances to the regulatory controls and administrative, civil and criminal sanctions applicable to Schedule I controlled substances. DOJ described the action as directed at deliberately manufactured and concentrated opioid products rather than traditional botanical kratom.

That changes the South Carolina debate: the state does not need a KCPA carve-out to “regulate” MP, MGM-15 or MGM-16 as ordinary consumer products. They are already Schedule I controlled substances under federal law.

DOJ also announced a limited enforcement-discretion policy for products in which only incidental trace amounts of MGPI are confirmed and the product is otherwise consistent with botanical kratom. DOJ emphasized that this does not create a legal exemption and does not change MGPI's Schedule I status. The policy does not apply to MGM-15, MGM-16, or products containing manufactured, concentrated, fortified or intentionally added MGPI.

This makes the remaining South Carolina question even more basic: what is the state trying to preserve in the retail kratom market, and how will it independently distinguish botanical material from concentrated 7-OH or chemically manipulated products? A percentage on paper does not test a tablet. A certificate of analysis does not inspect a gas station. And a statutory distinction between “natural” and “synthetic” only works when regulators can actually determine what is sitting on the shelf.

The Question South Carolina Still Has to Answer

South Carolina's record shows multiple competing approaches: a numerical 7-OH cap, a “fully synthetic” distinction, broad Schedule I treatment, a 2% KCPA rewrite, a 20 mg proposal, certificates of analysis and retail-location restrictions. Those are materially different systems.

The enforcement question is therefore unavoidable: who tests the product, how often, against which validated method, with what lot traceability, and how does the state establish whether the chemistry and manufacturing pathway match the label?

Micah Knox was a person, not a statutory threshold. His family's story puts the consequences of that policy debate outside the State House and inside an ordinary retail market.